StimLabs

What StimLabs does

StimLabs is a privately held regenerative medicine company headquartered in Roswell, Georgia, founded in 2015 by John Daniel. The company develops and commercializes placental tissue allografts and collagen matrix medical devices for the management of acute and chronic wounds, including diabetic foot ulcers, venous ulcers, pressure ulcers, surgical wounds, trauma wounds, and burns. Its core technical platform is the patented Clearify process, which retains all three layers (amnion, intermediate layer, and chorion) of native placental membrane without delamination, preserving over 900 signaling components including growth factors, collagens, and proteoglycans. The portfolio spans 12+ products organized into Office-Based Solutions (Allacor P, Derma-Gide, Relese, Revita, Cogenex) and Hospital-Based Solutions (Architect Fx, Corplex P, Vialize, Enverse, Revita Burn Clear), with additional Geistlich-distributed products (DermaForm) and is supported by BriDGE crosslinking technology for equine pericardium ECM devices.

StimLabs generates revenue through direct sales of HCT/P and medical device products to healthcare providers, reimbursed via HCPCS Q-codes and A-codes (most recently A2035 effective April 2025 for Corplex P/Allacor P). The company operates a nationwide field sales team, holds GPO contracts with Vizient (awarded August 2025) and Premier (March 2024), maintains government agreements with the VA and DoD, and runs an exclusive national distribution partnership with Switzerland-based Geistlich (established November 2024 and expanded January 2026). Supporting services include industry-leading IVR turnaround, a Field Reimbursement team, pre/post-verification tools, and a provider portal with online payment processing.

The business is founder-owned and has grown organically without disclosed institutional investment rounds. Regulatory positioning is unusually broad for the company's size: FDA 21 CFR Parts 820 and 1271 compliance, ISO 13485:2016 certification, AATB Tissue Bank Accreditation (#00243, valid through November 2028), FDA Establishment Registration, and tissue bank licenses across seven states. The company has expanded its physical footprint from 16,000 to over 70,000 square feet across multiple campuses.

Name

StimLabs

Legal name

Stimlabs LLC

Website

https://stimlabs.com

Company type

Private

Founded year

2015

Operating status

Operating

Short description

StimLabs is a privately held regenerative medicine company founded in 2015 that develops placental tissue allografts and collagen matrix devices for chronic and acute wound care, selling directly to healthcare providers across podiatry, dermatology, surgery, and wound care specialties via GPO contracts and a Geistlich distribution partnership.

Ownership category

akta.pro rank

Product category

Regenerative Medicine Wound Care

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112), Medical Equipment and Supplies Manufacturing (3391)

SIC

Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE)

akta.pro secondary industry

Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG)

Keywords

• Regenerative wound care
• Placental tissue allografts
• Extracellular matrix devices
• Advanced wound management
• Medical device manufacturing

Headquarters

HQ city

Roswell

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Medical Device and HCT/P Product Sales: StimLabs manufactures and distributes medical devices and Human Cell, Tissue, and Cellular and Tissue-Based Products (HCT/Ps) for wound care. Products are sold to healthcare providers including physicians, wound care centers, hospitals, and clinics. Revenue is generated through product sales with payment terms typically net 30 days.
2. Reimbursement and Billing Services: Company provides IVR (Insurance Verification Request) services, field reimbursement support, and pre/post-verification support for healthcare providers billing Medicare, Medicaid, or other third-party payors for products.

Pricing tiers

Go-to-market motion2 records

Distribution channels5 records

Marketing channels6 records

Core offering

StimLabs manufactures and distributes medical devices and Human Cell, Tissue, and Cellular and Tissue-Based Products (HCT/Ps) for wound care and surgical applications. The company produces FDA 510(k) cleared placental tissue allografts, human umbilical cord-derived devices, and collagen matrix wound dressings sold to healthcare providers including physicians, podiatrists, dermatologists, surgeons, wound care centers, hospitals, and clinics. Revenue is generated primarily through product sales with supporting reimbursement and billing services including Insurance Verification Requests and field reimbursement support.

Product overview

StimLabs is a regenerative medicine company offering a comprehensive portfolio of placental tissue-based medical devices and advanced wound care products. The portfolio is organized into Office-Based Solutions (Allacor P, Derma-Gide, Relese, Revita, Cogenex) and Hospital-Based Solutions (Architect Fx, Corplex P, Vialize, Enverse, Revita Burn Clear). The company also distributes Geistlich products (DermaForm, Derma-Gide). Products utilize either the patented Clearify technology for placental membrane processing (retaining all three layers: amnion, intermediate layer, chorion), or specialized technologies for human umbilical cord-derived devices. The portfolio addresses various wound types including chronic wounds (diabetic ulcers, venous ulcers, pressure ulcers), acute wounds, surgical wounds, and burns, with multiple configurations (particulate, sheet, fenestrated) to meet diverse clinical needs.

Differentiator

Problem solved

Functional benefit

Brands

• Revita: Lyophilized dehydrated complete human placental membrane (dCHPM) allograft intended for use as a wound covering or barrier membrane.
• Cogenex
• Enverse
• Vialize
• Relese
• Corplex P
• Allacor P
• Architect Fx
• Derma-Gide
• DermaForm
• Theracor
• Revita Burn Clear
• Clearify

Products and services

• Allacor P The first and only FDA 510(k) cleared human umbilical cord-derived particulate medical device for wound management, providing a porous scaffold comprised of diverse human ECM components for management of damaged or deficient tissue in complex tissue defects.
• Derma-Gide Porcine-derived advanced wound care matrix device for management of chronic and acute wounds, featuring a bi-layered design with an upper compact layer mimicking basement membrane and a lower porous layer that facilitates cell ingrowth and re-epithelialization.
• Relese Fenestrated dehydrated complete human placental membrane (dCHPM) allograft acting as a selective barrier providing protection for acute and chronic wounds while allowing wound exudate to drain, using patented Clearify technology to retain all three layers of native placental membrane.
• Revita The first full thickness, intact lyophilized dehydrated complete human placental membrane (dCHPM) allograft retaining all three native placental membrane layers (amnion, intermediate layer, and chorion) and containing over 875 cytokines and growth factors.
• Cogenex Fenestrated dehydrated complete human placental membrane (dCHPM) allograft acting as a selective barrier offering protection to acute and chronic wounds while allowing wound fluid to drain, using patented Clearify technology to retain all three layers and 3D architecture of native tissue.
• Architect Fx Decellularized and dehydrated equine pericardium collagen matrix wound dressing manufactured using BriDGE technology that crosslinks collagen in ECM to prevent premature degradation by excessive proteolytic enzymes, enabling durable long-term wear for chronic and acute wound management.
• Corplex P Dehydrated human umbilical cord particulate (dHUCP) medical device formatted as particulate for management of damaged or deficient tissue, providing a porous scaffold of human ECM components and facilitating a moist wound environment through moisture exchange regulation.
• Vialize Lyophilized dehydrated complete human placental membrane (dCHPM) allograft designed for hospital use as wound covering or barrier membrane, retaining all three layers using patented Clearify technology with 4x thickness and 6x more growth factors than competitor grafts.
• Enverse Translucent dehydrated complete human placental membrane (dCHPM) allograft designed as a wound covering or barrier membrane over chronic and acute wounds, using patented Clearify technology to retain all three layers of native placental membrane without separation.
• Revita Burn Clear Translucent dCHPM allograft ideal for covering large wounds including burns, acting as a barrier membrane or wound covering to protect wounds from the surrounding environment and developed with patented Clearify technology preserving all three layers of placental membrane.
• DermaForm Collagen scaffold particulate wound care device designed for chronic and acute wounds, FDA 510(k) cleared through collaboration with Geistlich, representing a portfolio milestone for StimLabs' range of wound care solutions.
• Theracor First human umbilical cord-derived medical device sheet, FDA cleared, representing StimLabs' expansion into sheet-format umbilical cord-derived products for wound management.

Quantifiable outcome

• 92% of wounds healed at 12 weeks with 93.6% wound area reduction
• +4 more outcomes

Named customers8 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Five partnerships are on record, tiered core and minor.

• VizientcoreChannel Partner/ Reseller/ Distributor · 4 August 2025Vizient awarded StimLabs a Regenerative Biologics Contract in August 2025. Vizient is a leading healthcare performance improvement company that serves as a group purchasing organization (GPO) for healthcare providers.
• GeistlichcoreChannel Partner/ Reseller/ Distributor · 26 November 2024Exclusive national distribution agreement established November 2024 for Geistlich's wound care portfolio including Derma-Gide. Collaboration on DermaForm collagen scaffold particulate wound care device with FDA 510(k) clearance achieved February 2026. Expanded partnership announced January 2026 for additional novel wound care product expected Q2 2026. Geistlich is a Swiss family-owned company with tradition since 1851, 15 subsidiaries, 120 distributors, reaching over 100 markets, employing approximately 900 people globally.
• Premier, Inc.coreChannel Partner/ Reseller/ Distributor · 5 March 2024StimLabs was awarded a Reconstructive Skin Grafting Products Agreement with Premier, Inc. in March 2024. Premier is a healthcare improvement company providing group purchasing services to healthcare providers.
• U.S. Department of Veterans Affairs (VA) and Department of Defense (DoD)coreChannel Partner/ Reseller/ Distributor · 10 December 2018StimLabs announced agreements with the VA and DoD healthcare systems in December 2018 for access to government healthcare facilities.
• American Military Medical Organization, LLCminorStrategic or Co-development Partner · 1 August 2017Partnership announced August 2017 for military medical applications of regenerative medicine products.

Scale indicators6 records

Recent moves8 records

Expansion highlights4 records

Emerging players

• Arthrex: Major orthopedic medical device company that has expanded into regenerative wound care with amniotic and placental membrane products. While primarily orthopedic-focused, Arthrex competes in overlapping ambulatory surgery center and podiatry accounts.

Broad incumbents

• Smith+Nephew: Broad incumbent in advanced wound management with amnioctic membrane products and a global sales force reaching hospitals and wound care centers. Competes with StimLabs across the full wound care continuum from chronic to surgical wounds.
• ConvaTec: Broad incumbent in advanced wound care with Aquacel, Foam, and antimicrobial dressings. While more focused on traditional dressings than biologicals, ConvaTec competes for the same hospital and wound care center formulary slots and physician relationships.
• Integra LifeSciences: Broad incumbent in regenerative wound care and surgical devices with Integra Dermal Regeneration Template and a broad wound care portfolio. Operates across multiple medical device categories with significant scale advantages and established hospital contracts overlapping with StimLabs' target facilities.
• Coloplast: Broad incumbent in wound care with Biatain and other foam/hydrocolloid dressings. Targets overlapping customer segments (wound care nurses, podiatrists, hospitals) with a more diversified ostomy and continence care portfolio.

Direct peers

• Organogenesis: Direct competitor in advanced wound care and skin substitutes with Apligraf, Dermagraft, and PuraPly products. Both companies serve podiatry, dermatology, and wound care centers with biologically-derived wound healing products reimbursed under similar HCPCS frameworks.
• AlloSource: Non-profit tissue bank producing allograft products for wound care, sports medicine, and orthopedic applications. Operates as a peer tissue processor with similar regulatory framework (AATB accredited, FDA registered) and overlapping hospital customer base.
• MIMEDX Group: Direct competitor in placental tissue allografts. MIMEDX uses the Purion process (originally co-conceptualized by StimLabs founder John Daniel and sold via Surgical Biologics), competing head-to-head with StimLabs' Clearify products like Revita, Cogenex, and Enverse across wound care and surgical applications.
• MTF Biologics: Non-profit tissue bank offering placental and dermal allografts (AmnioBand, AlloPatch) that compete with StimLabs' products in wound care and surgical applications. Similar business model as a tissue processor with hospital and GPO distribution.
• TissueTech (Amniox Medical): Direct peer in amniotic membrane-based wound care products (NEOX, CLARIX). Competes with StimLabs in podiatry, ophthalmology, and surgical applications using cryopreserved and dehydrated placental/umbilical cord tissue allografts.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/stimlabs-llc
• YouTubebit.ly/4j8V9YL
• Xbit.ly/3YTofV3
• Facebookbit.ly/43BIBoi
• Instagrambit.ly/43qhuLM

Compliance13 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about StimLabs